2. Academic Validation
  3. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats

Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats

  • J Parkinsons Dis. 2021;11(3):1023-1046. doi: 10.3233/JPD-202400.
Juho-Matti Renko 1,  Arun Kumar Mahato 2,  Tanel Visnapuu 1,  Konsta Valkonen 1 2,  Mati Karelson 3,  Merja H Voutilainen 1 2,  Mart Saarma 2,  Raimo K Tuominen 1,  Yulia A Sidorova 2
Affiliations

Affiliations

  • 1 Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • 2 Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.
  • 3 Institute of Chemistry, University of Tartu, Tartu, Estonia.
PMID: 34024778 DOI: 10.3233/JPD-202400
Abstract

Background: Parkinson's disease (PD) is a progressive neurological disorder where loss of dopamine neurons in the substantia nigra and dopamine depletion in the striatum cause characteristic motor symptoms. Currently, no treatment is able to halt the progression of PD. Glial cell line-derived neurotrophic factor (GDNF) rescues degenerating dopamine neurons both in vitro and in animal models of PD. When tested in PD patients, however, the outcomes from intracranial GDNF infusion paradigms have been inconclusive, mainly due to poor pharmacokinetic properties.

Objective: We have developed drug-like small molecules, named BT compounds that activate signaling through GDNF's receptor, the transmembrane receptor tyrosine kinase RET, both in vitro and in vivo and are able to penetrate through the blood-brain barrier. Here we evaluated the properties of BT44, a second generation RET agonist, in immortalized cells, dopamine neurons and rat 6-hydroxydopamine model of PD.

Methods: We used biochemical, immunohistochemical and behavioral methods to evaluate the effects of BT44 on dopamine system in vitro and in vivo.

Results: BT44 selectively activated RET and intracellular pro-survival Akt and MAPK signaling pathways in immortalized cells. In primary midbrain dopamine neurons cultured in serum-deprived conditions, BT44 promoted the survival of the neurons derived from wild-type, but not from RET knockout mice. BT44 also protected cultured wild-type dopamine neurons from MPP+-induced toxicity. In a rat 6-hydroxydopamine model of PD, BT44 reduced motor imbalance and seemed to protect dopaminergic fibers in the striatum.

Conclusion: BT44 holds potential for further development into a novel, possibly disease-modifying, therapy for PD.

Keywords

AKT pathway; BT44; MAPK pathway; Parkinson’s disease; RET agonist; glial cell line-derived neurotrophic factor; neuroprotection; rat 6-hydroxydopamine (6-OHDA) model; receptor tyrosine kinase RET.

Figures
Products